hVIVO plc Exercise of Share Options (8274H)
November 20 2018 - 1:00AM
UK Regulatory
TIDMHVO
RNS Number : 8274H
hVIVO plc
20 November 2018
HVIVO PLC
("hVIVO" or the "Company")
Exercise of Share Options
London, UK, 20 November 2018: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral and allergen challenge, announces
that, following the exercise of employee share options, application
has been made to AIM for the admission of 12,098 new ordinary
shares of 5.0p each (the "New Ordinary Shares").
Admission to trading on AIM of the New Ordinary Shares
("Admission"), which will rank pari passu in all respects with the
Company's existing shares in issue, is expected to occur on 23
November 2018.
Following Admission, the total number of ordinary shares with
voting rights in issue will be 80,593,592 and this figure may be
used by shareholders as the denominator for the calculations by
which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company under
the Financial Conduct Authority's Disclosure and Transparency
Rules.
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (Director, Investor Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Michael Burke (Corporate
Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO plc ("hVIVO") is pioneering a human-based clinical trial
platform to accelerate drug and vaccine development in respiratory
and infectious diseases. Leveraging human disease models in flu,
RSV, HRV and respiratory indications, the hVIVO platform captures
disease in motion, illuminating the entire disease life cycle from
healthy to sick and back to health. Based in the UK, market leader
hVIVO has conducted more than 50 clinical studies and inoculated
over 2500 volunteers.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IOELLFFTLLLALIT
(END) Dow Jones Newswires
November 20, 2018 02:00 ET (07:00 GMT)
Hvivo (LSE:HVO)
Historical Stock Chart
From Apr 2024 to May 2024
Hvivo (LSE:HVO)
Historical Stock Chart
From May 2023 to May 2024